封面
市场调查报告书
商品编码
1529384

全球筋膜室症候群治疗市场 - 2024-2031

Global Compartment Syndrome Treatment Market - 2024-2031

出版日期: | 出版商: DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2023年,全球筋膜室症候群治疗市场规模达3.168亿美元,预计2031年将达到5.166亿美元,2024-2031年预测期间复合年增长率为6.3%。

筋膜室症候群是一种痛苦的情况,当肌肉内的压力达到危险水平时就会发生。这种压力会减少血流量,阻止营养和氧气到达神经和肌肉细胞。筋膜室症候群可以是急性的(短期内出现严重症状),也可以是慢性的(长期持续)。

急性骨筋膜室症候群是一种外科急症。没有有效的非手术治疗方法。切口并切开覆盖受影响隔间的皮肤和筋膜。此手术称为筋膜切开术。

慢性骨筋膜室症候群是一种非手术治疗方法。物理治疗、矫正器(鞋垫)和抗发炎药物对于缓解症状的效果可能有限,通常无法恢復全面活动。

用于行为综合症治疗的药物包括鸦片类药物、非鸦片类药物和非类固醇抗发炎药。该市场是由创伤发生率增加和治疗技术进步等因素推动的。

市场动态:

司机

外伤发生率增加

全球筋膜室症候群治疗市场的需求是由多种因素所驱动的。外伤发生率的增加预计将推动市场的成长。交通事故、运动伤害和战斗伤害等外伤是导致骨筋膜室症候群的主要原因。

急性骨筋膜室症候群 (ACS) 最常在重大创伤后不久发生,尤其是长骨骨折。根据 2023 年 1 月的 Medscape 新闻报导,腹部筋膜室症候群在创伤 ICU 入院的频率为 5% 至 15%,在普通创伤入院的频率为 1%。

此外,该行业的主要参与者正在进行的研究将推动该市场的成长。根据 NCBI 2024 年 3 月的研究出版物,2015 年至 2022 年期间,共有 13,305 例创伤性骨筋膜室症候群病例。其中,61%出现在下肢,11%出现在上肢。很大一部分病例缺乏精确的定位分类(25.2%)。大多数创伤性骨筋膜室症候群发生在男性(女性 4092 例,男性 9213 例)。

同样,根据 EFFORT 2023 年 12 月的公开评论,胫骨骨折中的 ACS 根据损伤部位的不同而有所不同,胫骨平台骨折的 ACS 约为 12%,在高能量模式中高达 53%。

限制

治疗费用高昂、治疗选择有限以及个人意识和诊断有限等因素预计将阻碍市场。

有关此报告的更多详细资讯 - 索取样品

目录

目录

第 1 章:方法与范围

第 2 章:定义与概述

第 3 章:执行摘要

第 4 章:动力学

  • 影响因素
    • 司机
      • 外伤发生率增加
      • 治疗技术进步
    • 限制
      • 治疗费用高
    • 机会
    • 影响分析

第 5 章:产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章:按治疗类型

  • 筋膜切开术
  • 矫正器
  • 药品
    • 阿片类药物
    • 非阿片类药物
    • 非类固醇抗发炎药

第 7 章:按症状类型

  • 急性筋膜室症候群
  • 慢性筋膜室症候群

第 8 章:最终用户

  • 医院和诊所
  • 门诊手术中心
  • 其他的

第 9 章:按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章:竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章:公司简介

  • Stryker
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • BD
  • C2DX, Inc
  • Accuryn Medical
  • Medline Industries, LP.
  • MY01
  • Convatec Inc
  • RAUMEDIC AG
  • Millar, LLC
  • Mirador Biomedical

第 12 章:附录

简介目录
Product Code: PH8567

Overview

The global compartment syndrome treatment market reached US$ 316.8 million in 2023 and is expected to reach US$ 516.6 million by 2031 growing with a CAGR of 6.3% during the forecast period 2024-2031.

Compartment syndrome is a painful condition that occurs when pressure within the muscles builds to dangerous levels. This pressure can decrease blood flow, which prevents nourishment and oxygen from reaching nerve and muscle cells. Compartment syndrome can be either acute (having severe symptoms for a short period) or chronic (long-lasting).

Acute compartment syndrome is a surgical emergency. There is no effective nonsurgical treatment. An incision and cut open the skin and fascia covering the affected compartment. This procedure is called a fasciotomy.

Chronic compartment syndrome is a nonsurgical treatment. Physical therapy, orthotics (inserts for shoes), and anti-inflammatory medicines may be of limited benefit in relieving symptoms and generally do not allow a return to full activity.

Drugs used for comportment syndrome treatment involve opioids, non-opioids, and NSAIDs. The market is driven by factors such as the increasing incidence of traumatic injuries and technological advancements in treatment.

Market Dynamics: Drivers

Increasing incidence of traumatic injuries

The demand for the global compartment syndrome treatment market is driven by multiple factors. The increasing incidence of traumatic injuries is expected to drive the growth of the market. Traumatic injuries, such as road accidents, sports injuries, and combat injuries, are major causes of compartment syndrome.

Acute compartment syndrome (ACS) most often develops soon after significant trauma, particularly involving long bone fractures. According to Medscape news in January 2023, the frequency of abdominal compartment syndrome in trauma ICU admissions is anywhere from 5 to 15% and 1% of general trauma admissions.

Moreover, major players in the industry's ongoing research studies would propel this market growth. According to an NCBI research publication in March 2024, during the period from 2015 to 2022, a total of 13,305 cases of traumatic compartment syndromes. Of these, 61% manifested in the lower extremities and 11% in the upper extremities. A significant portion of cases lacked precise localization classification (25.2%). Most traumatic compartment syndromes occurred in males (4092 cases in females vs. 9213 in males).

Similarly, as per EFFORT open reviews in December 2023, ACS in tibial fractures varies depending on the injury site, around 12% for tibial plateau fractures, reaching up to 53% in higher-energy patterns.

Restraints

Factors such as the high cost of treatment, the availability of limited treatment options, and limited awareness & diagnosis among individuals, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global compartment syndrome treatment market is segmented based on treatment type, syndrome type, end-users, and region.

The fasciotomy segment accounted for approximately 51.3% of the global compartment syndrome treatment market share

The fasciotomy segment is expected to hold the largest market share over the forecast period. Fascia are the thick sheets of connective tissue that surround muscle compartments. Fasciotomy, a procedure in which the fascia is cut to relieve pressure in the muscle compartment, is used to treat people with acute or chronic compartment syndrome.

A fasciotomy consists of 1 or more fascial incisions and remains the only effective way to treat acute compartment syndrome. Fasciotomy is a surgical procedure that involves making an incision in the skin and underlying tissue to relieve pressure on the affected nerve or muscle. According to Healio news in April 2024, Atraumatic idiopathic compartment syndrome requiring emergent fasciotomy.

Moreover, key players in the market technological advancements in fasciotomy drive the market growth. The development of advanced intracompartmental pressure monitoring devices enhances the accuracy and reliability of diagnosing compartment syndrome, guiding surgeons in determining the necessity and timing of fasciotomy.

As per NCBI publication in March 2024, an FDA-approved device was used for continuous compartment pressure monitoring. The sensor tip is placed in the muscle belly, and the trochar is then detached from the sensor, allowing the sensor to remain in place. Innovations in imaging technologies, such as portable ultrasound devices, aid in pre-operative planning and intraoperative assessment during fasciotomy procedures.

Geographical Analysis

North America accounted for approximately 43.8% of the global compartment syndrome treatment market share.

North America region is expected to hold the largest market share over the forecast period owing to the high incidence of trauma and sports-related injuries as per NCBI April 2024, the incidence of ACS is estimated to be 7.3 per 100,000 in males and 0.7 per 100,000 in females.

According to the National Safety Council in 2023, 3.7 million people were treated in emergency departments for injuries involving sports and recreational equipment. The activities most frequently associated with injuries are exercise, cycling, and basketball. Amongst American children and adolescents, sports and recreational activities contribute to the growth of the market.

Moreover, key player's innovative initiatives, growing awareness of the syndrome, advancements in medical technology, and increased focus on sports medicine propel this market growth in this region. For instance, in August 2023, Sentinel Medical Technologies addressed the IAP transducer shortage with the trauma ward. IAP monitoring is a critical component of patient care in OR and ICU settings. It serves as a crucial guide for medical teams in assessing the risk of developing Intra-Abdominal Hypertension (IAH) and Abdominal Compartment Syndrome (ACS), conditions that can have severe consequences if not addressed promptly.

Market Segmentation

By Treatment Type

  • Fasciotomy
  • Orthotics
  • Drugs
    • Opioids
    • Non-Opioids
    • NSAIDs

By Syndrome Type

  • Acute Compartment Syndrome
  • Chronic Compartment Syndrome

By End-User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • The rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the compartment syndrome treatment market include Stryker, BD, C2DX, Inc., Accuryn Medical, Medline Industries, LP., MY01, Convatec Inc., RAUMEDIC AG, Millar, LLC, and Mirador Biomedical among others.

Key Developments

  • In May 2021, MY01 Inc. received FDA clearance for the MY01 continuous compartment pressure monitor as an aid in the diagnosis of compartment syndrome.

Why Purchase the Report?

  • To visualize the global compartment syndrome treatment market segmentation based on treatment type, syndrome type, end-users, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of the compartment syndrome treatment market with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in Excel consisting of key products of all the major players.

The global compartment syndrome treatment market report would provide approximately 62 tables, 58 figures, and 181 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Syndrome Type
  • 3.3. Snippet by End-Users
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Incidence of Traumatic Injuries
      • 4.1.1.2. Technological Advancements in Treatment
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Fasciotomy *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Orthotics
  • 6.4. Drugs
    • 6.4.1. Opioids
    • 6.4.2. Non-Opioids
    • 6.4.3. NSAIDs

7. By Syndrome Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type Market Attractiveness Index, By Syndrome Type
  • 7.2. Acute Compartment Syndrome*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Chronic Compartment Syndrome

8. By End-Users

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 8.1.2. Market Attractiveness Index, By End-Users
  • 8.2. Hospitals & Clinics *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Stryker *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. BD
  • 11.3. C2DX, Inc
  • 11.4. Accuryn Medical
  • 11.5. Medline Industries, LP.
  • 11.6. MY01
  • 11.7. Convatec Inc
  • 11.8. RAUMEDIC AG
  • 11.9. Millar, LLC
  • 11.10. Mirador Biomedical

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us